838821-08-2

Usage

Uses

Used in Pharmaceutical Industry:
8-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-OL is used as a reactant in the preparation of bromotetralone, which is an important intermediate in the synthesis of arylindazoles and arylarenopyrazoles. These compounds have potential applications in the development of pharmaceuticals, particularly as therapeutic agents for various diseases.
Used in Organic Chemistry Research:
8-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-OL is also used as a starting material in the synthesis of various organic compounds, making it a valuable resource for researchers in the field of organic chemistry. Its unique structure allows for the exploration of new reaction pathways and the development of novel synthetic methods.

Upstream product

• 529-33-9 1,2,3,4-Tetrahydro-1-naphthol 
• 124-73-2 1,2-dibromo-1,1,2,2-tetrafluoroethane 
• 651735-60-3 8-bromo-3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 651735-60-3 8-bromo-3,4-dihydronaphthalene-1(2H)-one 
• 4106-24-5 1,3,4,5-tetrahydro-1-phenylbenz[cd]indazole 

Relevant academic research and scientific papers

METHODS FOR MAKING QUINOLINYLDIAMINES

The present disclosure provides methods for making quinolinyldiamine products from quinolinyl starting materials. In addition, the quinolinyldiamines can be used as ligands or ligand precursors for catalysts, e.g. for use in olefin polymerization.

Metal complexes, organic electroluminescent material, the organic electroluminescent element, electronic equipment (by machine translation)

The invention relates to metal complexes, comprising the metal complex of the organic electroluminescent material, organic light-emitting element and the electroluminescent device. The metal complex of the present invention of the formula M (LA )x (LB )y (Lc )z ; The invention comprising metal complexes of the light-emitting electroluminescent element is dark red, high luminous efficiency, at the same time good thermal stability of the material, the material is easy preparation, is easy to be purified, is used as an organic electroluminescent element is the ideal choice of light-emitting material. (by machine translation)

QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF

Quinolinyldiamido transition metal complexes are disclosed for use in alkene polymerization to produce multimodal polyolefins.

Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)

Various racemic and enantioenriched (trans)-X,Y-dihydroxy-X,Y-dihydronaphthoyl analogues as well as X-hydroxy-naphthoyl analogues of CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (1, Setipiprant/ACT-129968) were synthesized in order to gain insight into regio- and enantioselectivity of the metabolic oxidation of 1 and to verify the structures of four metabolites that were proposed earlier in a clinical ADME study. Analytical data of the synthetic standards were compared with data from samples of biological origin. The two major metabolites M7 and M9 were unambiguously verified as 2-(2-((trans)-3,4-dihydroxy-3,4-dihydronaphthalene-1-carbonyl)- and 2-(2-((trans)-5,6-dihydroxy-5,6-dihydronaphthalene-1-carbonyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid, respectively, each composed of two enantiomers with 68% and 44% ee in favor of (+)-(3S,4S)-M7 and (+)-(5S,6S)-M9, respectively. Likewise, minor metabolites M3 and M13 were identified as 2-(8-fluoro-2-(5-hydroxy-1-naphthoyl)- and 2-(8-fluoro-2-(4-hydroxy-1-naphthoyl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)acetic acid, respectively.

Pyridyldiamido Transition Metal Complexes, Production and Use Thereof

Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization.

PYRIDYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF

Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization.

Explorations into the potential of chiral sulfonium reagents to effect asymmetric halonium additions to isolated alkenes

While methods for the racemic dihalogenation and halohydroxylation of alkenes have been known for decades, enantioselective variants of these processes remain elusive. Initial attempts were made to overcome this long-standing challenge by exploring the potential of chiral, crystalline, sulfur-derived halonium reagents to accomplish the asymmetric dichlorination and iodohydroxylation of 1,2-dihydronaphthalene. Asymmetric dichlorination of this substrate was achieved in 57% yield and 14% enantiomeric excess (ee), but asymmetric iodohydroxylation was much more successful, giving 67% yield and 63% ee. Thorough studies were made of these processes, including investigation of various chiral sulfide derivatives, their substrate scopes, and the reaction conditions. Georg Thieme Verlag Stuttgart · New York.

Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides

(Chemical Equation Presented) Palladium-catalyzed cyclization of arylhydrazones of 2-bromoaldehydes and 2-bromoacetophenones to give 1-aryl-1H-indazoles has been studied in detail. The cyclization of arylhydrazone of 2-bromobenzaldehydes can be performed with good to high yields using Pd(dba)2 and chelating phosphines, of which the most effective are rac-BINAP, DPEphos, and dppf, in the presence of Cs2CO3 or K3PO4 as a base. Electron-rich, bulky ligands commonly employed for intermolecular amination such as PtBu3 and o-PhC6H4PtBu2 were shown to be ineffective for cyclization and to lead instead to extensive oligomerization and tarring. The method developed is applicable for preparation of a wide scope of indazoles bearing electron-donating or electron-withdrawing substituents, among them, unprotected carboxyl, as well as various indazole heteroanalogues. The cyclization of arylhydrazones of less reactive halides such as 2-chlorobenzaldehyde, as well as 2-bromoacetophenone and bromotetralone, has been achieved. The purity of the starting hydrazone has been shown to be a critical parameter, as various impurities inhibit the cyclization.